RPCA
XERS icon

Running Point Capital Advisors’s Xeris Biopharma Holdings XERS Stock Holding History

Running Point Capital Advisors’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-10,000
Closed -$13.3K – 208
2022
Q4 		$13.3K Hold
10,000
– – 0.01% 189
2022
Q3 		$16K Hold
10,000
– – 0.01% 188
2022
Q2 		$15K Hold
10,000
– – 0.01% 196
2022
Q1 		$26K Buy
+10,000
New +$24.4K 0.02% 177

Other funds holding XERS

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Running Point Capital Advisors's XERS Position: Q1 2023 in Review

Running Point Capital Advisors sold out of Xeris Biopharma Holdings (XERS) in Q1 2023, closing a stake of 10,000 shares — an estimated $13.3K sold.

Running Point Capital Advisors first reported a position in XERS in Q1 2022 and held it in 4 quarters. The position peaked at $26K in Q1 2022. 92 funds tracked by Wall St. Rank hold XERS as of Q1 2023.

  • Running Point Capital Advisors reported no remaining Xeris Biopharma Holdings position as of Q1 2023 after selling out during the quarter.
  • Running Point Capital Advisors sold 10,000 Xeris Biopharma Holdings shares in Q1 2023, an estimated $13.3K.
  • Running Point Capital Advisors first reported a position in Xeris Biopharma Holdings in Q1 2022 and held it in 4 quarters.
  • Running Point Capital Advisors's Xeris Biopharma Holdings position peaked at $26K in Q1 2022.
  • 92 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2023.

Based on Running Point Capital Advisors's 13F filing for Q1 2023, filed 10 May 2023.